NCT00375128已完成1 期
Assessment of Protection Against Malaria by Sporozoite Challenge of Healthy Adults Vaccinated With the Polyprotein Malaria Vaccines 'FP9-PP, MVA-PP' and Control Non-Vaccinated Volunteers
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 26
- 试验地点
- 4
- 主要终点
- Efficacy (time in hours to parasitaemia)
研究概览
简要总结
This study examines the ability of two new malaria vaccines (FP9-PP and MVA-PP) to prevent the development of malaria infection after controlled exposure to the parasite. Volunteers for this trial will have received these vaccines in the preceding trial VAC027.1.
详细描述
Malaria infection kills over 2 million people each year. It is a major problem for those who live in endemic areas and for travellers. There is clearly a great need for a safe effective malaria vaccine.
The purpose of this study is to test the clinical efficacy of two candidate malaria vaccines (FP9-PP and MVA-PP). These live viral vector vaccines were administered in a 'prime boost' regime in the preceding trial VAC027.1.
Volunteers will now be exposed to 5 infective bites from mosquitoes carrying P. falciparum malaria.
This trial will:
- Measure efficacy as the time in hours from malaria exposure to blood film positive for malaria parasites
- Examine immunogenicity before and after malaria infection
- Measure longer term vaccine efficacy by re-challenging any protected volunteers 6 - 12 months later
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy non-pregnant adults aged 18 to 50 years
- •The vaccinated group will be subjects who have received the vaccine regime described for group 6 or 7 in VAC027.1
- •Resident in or near Oxford, UK for the duration of the challenge study
- •For females only, willingness to practice effective contraception during the challenge study.
- •Agreement to refrain from blood donation during the course of the study
- •Written informed consent
- •Willingness to allow the investigators to access hospital and General Practitioner medical notes
- •Willingness to undergo an HIV test
排除标准
- •Any deviation from the protocol-defined normal range in biochemistry or haematology blood tests or in urine analysis
- •Prior receipt of an investigational malaria vaccine (unless administered in VAC027.1)
- •Use of any investigational or non-registered drug, live vaccine or medical device other than the study vaccine within 30 days preceding dosing of study vaccine, or planned use during the study period
- •Administration of chronic immunosuppressive drugs or other immune modifying drugs within six months of vaccination
- •History of malaria chemoprophylaxis with chloroquine within 5 months prior to the planned challenge, with Lariam within 6 weeks prior to the challenge, and Riamet within 2 weeks prior to the challenge
- •Any history of malaria
- •Travel to a malaria endemic country within the previous 3 months prior to the planned challenge
- •Planned travel to malarious areas during the study period
- •Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection and asplenia
- •Evidence of cardiovascular disease
- •History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ)
- •History of haemoglobinopathies
- •History of diabetes mellitus
- •Chronic or active neurological disease requiring ongoing specialist supervision
- •Chronic gastrointestinal disease requiring ongoing specialist supervision
- •History of > 2 hospitalisations for invasive bacterial infections (pneumonia, meningitis)
- •Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 42 units every week
- •Seropositive for hepatitis B surface antigen (HBsAg)
- •Seropositive for hepatitis C virus (antibodies to HCV)
- •Hepatomegaly, right upper quadrant abdominal pain or tenderness
- •Evidence of serious psychiatric condition
- •Any other on-going chronic illness requiring hospital specialist supervision
- •Acute disease at the time of enrolment
- •Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate
- •Pregnant or lactating female
- •Female who is willing or intends to become pregnant during the study
- •History of severe reactions or allergy to mosquito bites
- •PI assessment of lack of willingness to participate and comply with all requirements of the protocol
- •History or clinical evidence of intravenous drug abuse
- •Any other finding which in the opinion of the investigator would significantly increase the risk of having an adverse outcome from participating in this protocol
结局指标
主要结局
Efficacy (time in hours to parasitaemia)
次要结局
- Immunogenicity
研究者
研究点 (4)
Loading locations...
相似试验
已完成
1 期
Efficacy of Combined PEV3A Virosomal Vaccine and FP9-MVA ME-TRAP Prime Boost RegimenMalaria, FalciparumMalariaNCT00408668University of Oxford30
进行中（未招募）
不适用
Assessment of protection against malaria by sporozoite challenge of healthy adults vaccinated with AdCh63 ME-TRAP and MVA ME-TRAPMalariaEUCTR2008-006804-46-GBniversity of Oxford
进行中（未招募）
1 期
Assessment of protection against malaria by sporozoite challenge of healthy adults vaccinated with the virosomal vaccine PEV3A and FP9-MVA ME-TRAP - Efficacy of the malaria vaccines PEV3A and FP9-MVA ME-TRAPPlasmodium falciparum malariaEUCTR2005-001041-42-GBniversity of Oxford48
进行中（未招募）
不适用
Assessment of protection against malaria by sporozoite challenge of healthy adults vaccinated with AdCh63 ME-TRAP and MVA ME-TRAPMalariaEUCTR2007-004360-44-GBniversity of Oxford
已完成
1 期
Safety and Immunogenicity Study of the Malaria Vaccines FP9 PP and MVA PPMalaria, FalciparumMalariaNCT00374998European Vaccine Initiative35